Exchange: NASDAQ·Updated 07:32 PM EST

OM News

News
all
press releases
Outset Medical, Inc. (NASDAQ:OM) Stock Has Consensus Target Price of $10.00
Outset Medical, Inc. (NASDAQ:OM - Get Free Report) has been assigned an average recommendation of "Hold" from the five ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and t...
MarketBeat
Outset Medical, Inc. (NASDAQ:OM) Stock Has Consensus Target Price of $10.00
Outset Medical, Inc. (NASDAQ:OM - Get Free Report) has been assigned an average recommendation of "Hold" from the five ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and t...
MarketBeat
More News
Outset Medical, Inc. (NASDAQ:OM - Get Free Report) CEO Leslie Trigg sold 3,403 shares of the firm's stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $3.67, for a total transaction of $12,489.01. Following the completion of the sale, the chief executive...
MarketBeat
Outset Medical, Inc. (NASDAQ:OM - Get Free Report) CFO Renee Gaeta sold 4,498 shares of the firm's stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $3.67, for a total value of $16,507.66. Following the transaction, the chief financial officer owned...
MarketBeat
Outset Medical (OM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
Outset Medical (OM) delivered earnings and revenue surprises of -6.25% and +6.65%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
DaVita gains from IKC growth, improving treatment economics and stronger formulary adoption, but payer-mix pressures and costs remain concerns.
Zacks
HIMS' top line is driven by demand for weight loss, international and AI momentum, but margin pressure and FDA uncertainty remain.
Zacks
Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.
Zacks
Outset Medical (OM) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Zacks
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets

Advertisement|Remove ads.